Kim et al. combined their Toll-like receptor 7/8 agonist nanovaccine with free sunitinib and programmed death-ligand 1 (PD-L1) antibody, which, again, abrogated tumor-associated immune suppression and significantly decreased tumor weight in an in vivo experiment 120. This evidence concerns the gene CD274 and neoplasm.